Pamela Daher, MD
Colon & Rectal Surgery · Galveston, TXNPI 1588083984
Payments from drug & device makers
What this record shows
This record is dominated by education: $10,360 of the $14,016 with a category attached, or 73.9%. Intuitive Surgical accounts for 81.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $4,527 and has fallen 96.3% since, to $167 in 2025.
Across 44 payments — averaging $318.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- THD America, Inc.$2K
- Stryker$486
- Baxter Healthcare$121
- Hollister Incorporated$115
- Medtronic$88
- plus $149 from 6 others
What the payments were for
- Travel & lodging$1,73512%
- Food & beverage$1,91314%
- Education$10,36074%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $11,414 |
| THD America, Inc. | 9 | $1,643 |
| Stryker | 2 | $486 |
| Baxter Healthcare | 1 | $121 |
| Hollister Incorporated | 1 | $115 |
| Medtronic | 4 | $88 |
| AstraZeneca | 1 | $35 |
| Merck | 3 | $34 |
| Boston Scientific | 2 | $30 |
| Braintree Laboratories, Inc. | 1 | $21 |
| Hemosonics LLC | 1 | $16 |
| Kerecis Limited | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,241
- DAVINCI XI$3,000
- NONE$325
- SPY TECHNOLOGY$161
- No Related Product$121
- NEW IMAGE$115
How this compares
$14,016 in reported general payments places this provider in the 75th percentile of 200 colon & rectal surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MotegrityPrucalopride Succinate | 19 | $13,202 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 22 | $282 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $204 |
| Gabapentin | 27 | $156 |
| Neomycin Sulfate | 21 | $123 |
| Metronidazole | 25 | $117 |
| Tramadol Hcl | 18 | $41 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Galveston
- Anthony D'andreaGalveston$10K
- Thiru LakshmanAustin$756K
- Diego Marines CopadoHouston$462K
- Bidhan DasSugar Land$350K
- Christopher de JesusSan Antonio$201K
- Farshid AraghizadehFort Worth$181K
- Jefferson HurleyIrving$163K
- Erik AskenasyHouston$142K
- Eric HaasHouston$140K
- Robert JacobsonDallas$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.